BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 17684807)

  • 21. [Vaccination against cervical cancer and diseases caused by Human Papillomavirus].
    Bornstein J; Tuma R; Zarfati D; Ophir E
    Harefuah; 2007 Oct; 146(10):764-9, 814. PubMed ID: 17990391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus vaccine: a paradigm shift for pediatricians.
    Jenson HB
    Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
    Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
    Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the human papilloma vaccine on cervical cancer.
    Chan JK; Berek JS
    J Clin Oncol; 2007 Jul; 25(20):2975-82. PubMed ID: 17617529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement.
    Andrus JK; Sherris J; Fitzsimmons JW; Kane MA; Aguado MT
    Vaccine; 2008 Aug; 26 Suppl 10():K87-92. PubMed ID: 18847561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.
    Watson M; Shaw D; Molchanoff L; McInnes C
    Aust N Z J Public Health; 2009 Aug; 33(4):365-70. PubMed ID: 19689598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
    Franco EL; Cuzick J; Hildesheim A; de Sanjosé S
    Vaccine; 2006 Aug; 24 Suppl 3():S3/171-7. PubMed ID: 16844268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreasing risk: impact of HPV vaccination on outcomes.
    Hymel PA
    Am J Manag Care; 2006 Dec; 12(17 Suppl):S473-83. PubMed ID: 17203991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons from the failure of human papillomavirus vaccine state requirements.
    Schwartz JL; Caplan AL; Faden RR; Sugarman J
    Clin Pharmacol Ther; 2007 Dec; 82(6):760-3. PubMed ID: 17971822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
    Thomas TL
    Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age considerations when vaccinating against HPV.
    Wright TC; Huh WK; Monk BJ; Smith JS; Ault K; Herzog TJ
    Gynecol Oncol; 2008 May; 109(2 Suppl):S40-7. PubMed ID: 18482558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Human PAPILLOMA Virus (HPV) vaccine].
    Safra T
    Harefuah; 2007 Oct; 146(10):762-3, 814. PubMed ID: 17990390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-utility analysis of vaccination against HPV in Israel.
    Ginsberg GM; Fisher M; Ben-Shahar I; Bornstein J
    Vaccine; 2007 Sep; 25(37-38):6677-91. PubMed ID: 17706844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papillomavirus infection: an old disease, a new vaccine.
    Giles M; Garland S
    Aust N Z J Obstet Gynaecol; 2006 Jun; 46(3):180-5. PubMed ID: 16704468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The epidemiology behind the HPV vaccine discovery.
    Koutsky L
    Ann Epidemiol; 2009 Apr; 19(4):239-44. PubMed ID: 19344861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding and overcoming barriers to human papillomavirus vaccine acceptance.
    Zimet GD
    Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s23-8. PubMed ID: 16520681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chapter 15: HPV vaccine use in the developing world.
    Kane MA; Sherris J; Coursaget P; Aguado T; Cutts F
    Vaccine; 2006 Aug; 24 Suppl 3():S3/132-9. PubMed ID: 16950000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus vaccination: the policy debate over the prevention of cervical cancer--a commentary.
    Hoops KE; Twiggs LB
    J Low Genit Tract Dis; 2008 Jul; 12(3):181-4. PubMed ID: 18596458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.